EDGAR Filing Documents for 0001213900-19-004269

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:

SEC Accession No. 0001213900-19-004269

Filing Date

2019-03-15

Accepted

2019-03-15 17:02:12

Documents

Period of Report

2018-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	ANNUAL REPORT	f10k2018_actiniumpharma.htm	10-K	1145178
2	CERTIFICATE OF AMENDMENT TO ACTINIUM'S CERTIFICATE OF INCORPORATION	f10k2018ex3-7_actinium.htm	EX-3.7	1440
3	CONSULTING AGREEMENT, DATED DECEMBER 21, 2018, BETWEEN ACTINIUM PHARMACEUTICALS,	f10k2018ex10-37_actinium.htm	EX-10.37	65314
4	AMENDED AND RESTATED AT MARKET ISSUANCE SALES AGREEMENT, DATED DECEMBER 28, 2018	f10k2018ex10-38_actinium.htm	EX-10.38	267756
5	SEVENTH AMENDMENT TO THE 2013 AMENDED AND RESTATED STOCK PLAN, AS AMENDED	f10k2018ex10-39_actinium.htm	EX-10.39	8706
6	CONSENT OF GBH CPAS, PC.	f10k2018ex23-1_actinium.htm	EX-23.1	1815
7	CONSENT OF MARCUM LLP.	f10k2018ex23-2_actinium.htm	EX-23.2	2096
8	CERTIFICATION	f10k2018ex31-1_actinium.htm	EX-31.1	11969
9	CERTIFICATION	f10k2018ex31-2_actinium.htm	EX-31.2	11366
10	CERTIFICATION	f10k2018ex32-1_actinium.htm	EX-32.1	4892
11	CERTIFICATION	f10k2018ex32-2_actinium.htm	EX-32.2	4601
12	GRAPHIC	image_001.jpg	GRAPHIC	141323
19	GRAPHIC	page1.jpg	GRAPHIC	198897
20	GRAPHIC	page2.jpg	GRAPHIC	65029
	Complete submission text file	0001213900-19-004269.txt		5284633

Data Files

Seq	Description	Document	Type	Size
13	XBRL INSTANCE FILE	atnm-20181231.xml	EX-101.INS	599096
14	XBRL SCHEMA FILE	atnm-20181231.xsd	EX-101.SCH	44699
15	XBRL CALCULATION FILE	atnm-20181231_cal.xml	EX-101.CAL	37707
16	XBRL DEFINITION FILE	atnm-20181231_def.xml	EX-101.DEF	202521
17	XBRL LABEL FILE	atnm-20181231_lab.xml	EX-101.LAB	342498
18	XBRL PRESENTATION FILE	atnm-20181231_pre.xml	EX-101.PRE	290758

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016

Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875

Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)